Amal Parikh Stock Portfolio: Holdings and Sector Breakdown
Amal Parikh Stock Portfolio: What He Holds Right Now
Amal Parikh’s disclosed public shareholding is valued at Rs 276.25 crore across 4 stocks, according to the latest quarterly exchange filings. That is down 19.35% from the previous quarter. Here is a full breakdown of the holdings, sector weights, and what changed recently.
This information comes from shareholding pattern disclosures that Indian listed companies file with stock exchanges every quarter, compiled here by Trendlyne. Only stakes of 1% or more in a company show up in this data, since that is the legal disclosure threshold for individual shareholders.
Portfolio Snapshot
| Metric | Value |
|---|---|
| Portfolio value | Rs 276.25 crore |
| Quarterly change | -19.35% |
| Number of stocks | 4 |
| Top sector | Pharmaceuticals & Biotechnology (83.18%) |
The nearly 20% drop in portfolio value this quarter is worth noting, but it does not necessarily mean Parikh sold a large chunk of his holdings. A decline of this size can also come from stock price movement in a pharma-heavy portfolio, where individual stocks can swing sharply on news like drug approvals, regulatory inspections, or earnings misses.
Top Holdings
Shilpa Medicare: Rs 180.05 Crore
Shilpa Medicare is a pharmaceutical company involved in active pharmaceutical ingredient (API) manufacturing and formulations, including work in oncology and biosimilars. At Rs 180.05 crore, it is by far the largest position in this portfolio, making up roughly two-thirds of the total disclosed value.
Given that Pharmaceuticals & Biotechnology accounts for 83.18% of the sector mix, Shilpa Medicare is clearly the anchor holding here, alongside at least one other pharma name in the portfolio.
Panacea Biotec: Rs 49.72 Crore
Panacea Biotec is a healthcare company known for its work in vaccines and biopharmaceuticals. This holding is also where the notable recent activity took place. The quarterly filing shows a 1.47% increase in this stake, the only disclosed buying move for the period.
Sundrop Brands: Rs 39.41 Crore
Sundrop Brands operates in the FMCG (fast-moving consumer goods) space, and this holding lines up with the 14.27% sector weight assigned to FMCG in the portfolio. At Rs 39.41 crore, it is a meaningful but secondary position compared to the pharma-heavy core.
The Fourth Holding
The portfolio includes a fourth stock that falls under the Media sector, which makes up 2.56% of the overall sector allocation. Specific value figures for this position were not part of the top holdings list disclosed.
Sector Allocation Explained
| Sector | Weight |
|---|---|
| Pharmaceuticals & Biotechnology | 83.18% |
| FMCG | 14.27% |
| Media | 2.56% |
More than 8 out of every 10 rupees in this portfolio sits in pharma and biotech stocks. That is a heavily concentrated sector bet. Pharma stocks can be more volatile than broad market indices because their fortunes are tied to drug pipeline results, US FDA inspection outcomes, and patent-related developments, all of which can move stock prices quickly in either direction.
India’s pharmaceutical industry is one of the largest generic drug producers in the world, supplying medicines to markets across the US, Europe, and Africa, alongside the domestic market. Companies in this space often deal with a mix of regulated markets, where US FDA approval and inspection outcomes can significantly affect revenue, and semi-regulated or domestic markets, where competition and pricing dynamics work differently. This context helps explain why a portfolio this concentrated in pharma can see sharp swings in value from one quarter to the next, even without any change in the number of shares held.
Why the Sector Mix Matters More Than the Stock Count
With just 4 stocks, this portfolio might look small at first glance, but the real story is in the sector concentration. A four-stock portfolio spread evenly across four different industries behaves very differently from one where 83% of the value sits in a single sector.
For Amal Parikh’s portfolio, this means the health of India’s pharmaceutical and biotech industry as a whole, not just the performance of any one company, plays an outsized role in how the total portfolio value moves each quarter. This is worth remembering when reading the topline quarterly change figure.
What Changed This Quarter
- Panacea Biotec, up 1.47%, the standout move this quarter and the only disclosed buying activity.
- No selling activity was disclosed for any holding in this portfolio during the quarter.
Given that no sales were reported, the 19.35% drop in overall portfolio value likely reflects price declines in the underlying stocks rather than Parikh reducing his positions.
How Shareholding Disclosures Work
SEBI rules require listed Indian companies to publish their full shareholding pattern every quarter, and this includes naming any public (non-promoter) shareholder who holds 1% or more of the company’s equity. This is why data like Amal Parikh’s portfolio becomes visible at all. It is not a voluntary disclosure by the investor; it is a mandatory filing by the company.
A few important limits to keep in mind:
- Sub-1% holdings are invisible. If Parikh owns smaller stakes in other companies, this data would not capture them.
- The data lags real time. Quarterly filings mean there can be a gap of weeks between an actual portfolio change and its public disclosure.
- We don’t know the buy price. The Rs 180.05 crore value for Shilpa Medicare, for example, reflects current market price, not what was originally paid.
- Position sizes reflect one person’s risk appetite. An 83% weight in pharma stocks might suit an investor with deep sector knowledge and high risk tolerance, but it would be an aggressive allocation for most retail portfolios.
Should You Follow This Portfolio Blindly?
A heavily pharma-concentrated portfolio like this carries real risk alongside potential reward. Regulatory setbacks, failed drug trials, or export restrictions can hit pharma stocks hard and fast.
Before treating any of these holdings as a buy signal, it is worth doing independent research: checking the company’s recent quarterly results, debt levels, pipeline of new products, and how the stock is valued compared to peers. Large disclosed investors often have information, timing, or risk tolerance that ordinary investors don’t share, so use this data as a lead for research, not a shortcut for a decision.
Summary
Amal Parikh’s Rs 276.25 crore portfolio leans heavily on pharmaceuticals, led by Shilpa Medicare and Panacea Biotec, with FMCG exposure through Sundrop Brands and a small Media position rounding things out. The only disclosed move this quarter was an increase in Panacea Biotec, while the overall portfolio value fell 19.35%, most likely due to price movement rather than active selling.
FAQ
What is Amal Parikh’s total stock portfolio worth?
His disclosed public shareholding stands at Rs 276.25 crore across 4 stocks as per the latest quarterly filing.
Which stock does Amal Parikh hold the most of?
Shilpa Medicare is his largest holding at Rs 180.05 crore, making pharmaceuticals the dominant sector in his portfolio.
Did Amal Parikh sell any stocks recently?
No selling activity was disclosed for this portfolio in the latest quarter.
Why did Amal Parikh’s portfolio value drop by almost 19%?
Since no sales were disclosed, the drop likely reflects a decline in the market price of his holdings rather than him exiting positions.
What sectors is Amal Parikh most invested in?
Pharmaceuticals & Biotechnology makes up 83.18% of the portfolio, followed by FMCG at 14.27% and Media at 2.56%.
Is Panacea Biotec a new position for Amal Parikh?
The filing shows a 1.47% increase in this holding, which could reflect either a new stake or a top-up to an existing one.
Key Takeaways
- Amal Parikh’s disclosed portfolio is worth Rs 276.25 crore, down 19.35% for the quarter.
- The portfolio spans 4 stocks, led by Shilpa Medicare at Rs 180.05 crore.
- Pharmaceuticals & Biotechnology dominates at 83.18% of sector weight.
- Panacea Biotec saw a 1.47% increase, the only disclosed buying activity this quarter.
- No sales were reported, so the value drop likely reflects price movement, not an exit.
